FDA Final Rule – Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations

The purpose of the document is to present key facts about the FDA’s new final rule — 21 CFR 50.22 — which allows an Institutional Review Board (IRB) to waive or alter some or all informed-consent requirements for certain clinical investigations that pose no more than minimal risk to participants.

Download